top of page

 
業績|論文・出版物|目次|ALL
 

Comparison of human biopsy-derived and human iPS cell-derived intestinal organoids established from a single individual

Inu T., Yamashita T., Tomita J., Yokota J., Kishimoto W., Nakase H., Mizuguchi H.

Drug Metab Pharmacokinet, In press.

ヒトiPS細胞を用いた食の評価系 ~ヒトiPS細胞から分化誘導した腸管上皮細胞~

水口裕之

実験医学, In press.

新規アデノウイルス製剤 ~非増殖型ベクターと腫瘍溶解性ウイルス~

水口裕之

医学のあゆみ, In press.

アデノウイルスベクター

水口裕之

遺伝子細胞治療ハンドブック, In press.

Treatment of human pancreatic cancers following local and systemic administration of oncolytic adenovirus serotype 35.

Ono R., Takayama K., Onishi R., Tokuoka S., Sakurai F., Mizuguchi H.

Anticancer Res., 43, 537-546 (2023)

Biliary epithelial cell differentiation of bipotent human liver-derived organoids by 2D and 3D culture.

Tong Y., Ueyama-Toba Y., Mizuguchi H.

Biochem. Biophys. Rep., 33, 101432 (2023)

Pre-treatment of oncolytic reovirus improves tumor accumulation and intratumoral distribution of PEG-liposomes.

Eguchi M., Hirata S., Ishigami I., Shuwari N., Ono R., Tachibana M., Tanuma M., Kasai A., Hashimoto H., Ogawara KI., Mizuguchi H., Sakurai F.

J. Cont. Rel., 354, 35-44 (2023)

Establishment of MDR1-knockout human enteroids for pharmaceutical application

Inu T., Nomoto R., Yokota J., Yamashita T., Okada K., Kishimoto W., Nakase H., Mizuguchi H.

Drug Metab Pharmacokinet, 48, 100476 (2023)

腫瘍溶解性ウイルスによる抗腫瘍免疫の活性化とがん免疫療法との併用

櫻井文教、水口裕之

ドラックデリバリーシステム, 38, 24-30 (2023)

WebSite

Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.

Tazawa H., Shigeyasu K., Noma K., Kagawa S., Sakurai F., Mizuguchi H., Kobayashi H., Imamura T., Fujiwara T.

Cancer Sci., 113, 1919-1929 (2022)

Adenovirus vector-based vaccine for infectious diseases.

Sakurai F., Tachibana M., Mizuguchi H.

Drug Metab. Pharmacokinet., 42, 100432 (2022)

ZFAND3 Overexpression in the Mouse Liver Improves Glucose Tolerance and Hepatic Insulin Resistance.

Shimizu K., Ogiya Y., Yoshinaga K., Kimura H., Michinaga .S, Ono M., Taketomi A., Terada T., Sakurai F., Mizuguchi H., Tomita K., Nishinaka T.

Exp. Clin. Endocrinol. Diabetes, 130, 254-261 (2022)

A dopamine antagonist, domperidone, enhances the replication of an oncolytic adenovirus in human tumor cells.

Nishimae F., Sakurai F., Ono R., Onishi R., Takayama K., Mizuguchi H.

J. Gen. Virol, 103, 1752 (2022)

Adenovirus vector with ADP gene induces cytopathic effects in HEK293 cells without significant elevation of virus titers.

Shiota A., Nishimae F., Sakurai F., Mizuguchi H.

Anticancer Res., 42, 1719-1727 (2022)

Decellularized Organ-Derived Scaffold Is a Promising Carrier for Human Induced Pluripotent Stem Cells-Derived Hepatocytes.

Kojima H., Yagi H., Kushige H., Toda Y., Takayama K., Masuda S., Morisaku T., Tsuchida T., Kuroda K., Hirukawa K., Inui J., Nishi K., Nakano Y., Tanaka M., Hori S., Hasegawa Y., Abe Y., Kitago M., Adachi S., Tomi M., Matsuura K., Mizuguchi H., Kitagawa Y.

Cells, 11, 1258 (2022)

A doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine.

Bai, L., Tachibana, K., Murata, M., Inoue, T., Mizuguchi, H., Maeda, S., Ikemura, K., Okuda, M., Kusakabe, T., Kondoh, M.

Toxicol Lett., 370, 1-6 (2022)

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.

Ono R., Nishimae F., Wakida T., Sakurai F., Mizuguchi H.

Sci. Rep., 12, 21560 (2022)

Modified method for differentiation of myeloid-derived suppressor cells in vitro enhances immunosuppressive ability via glutathione metabolism.

Zhou H., Zhiqi X., Morikawa N., Sakurai F., Mizuguchi H., Okuzaki D., Okada N.. Tachibana M.

Biochem. Biophys. Rep., 33, 101416 (2022)

Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation and tumor infiltration of natural killer cells

Ono R., Sakurai F., Tokuoka S., Ishii K., Mizuguchi H

BioRxiv (2022)

アデノウイルスベクターワクチンの現状と展望

水口裕之、立花雅史、櫻井文教

ドラッグデリバリーシステム, 37, 421-428 (2022)

bottom of page